drugset / Trial / NCT02009332
Phase 1/2 Study of ABI-009 in Nonmuscle Invasive Bladder Cancer
Non-randomizedSequentialOpen-labelTreatment
Summary
Purpose of this study is to determine appropriate dosing of ABI-009 and evaluate the safety and anti-tumor activity of ABI-009 in treatment of non-muscle invasive bladder cancer
Timeline
- Start
- 2014-04-09
- Primary completion
- 2019-12-01
- Completion
- 2019-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gemcitabine | Small molecule | 2000 mg | Other |
| Subject | Sirolimus | Small molecule | 100 mg | Other |
| Subject | Sirolimus | Small molecule | 200 mg | Other |
| Subject | Sirolimus | Small molecule | 300 mg | Other |
| Subject | Sirolimus | Small molecule | 400 mg | Other |